Miscellaneous
The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence. To beat these odds, life sciences leaders must know when to continue funding a promising, new product and when to call it quits. In this episode of BDO’s Health & Life Sciences Rx Podcast, BDO’s Howard Levine sits down with leaders from the Allen Institute for Brain Science, Comet Therapeutics, and McDermott Will & Emery to discuss how life sciences leaders can evaluate whether to continue pursuing a drug development program or cancel it. Tune in for insights into: Why a “fast to failure” mentality is key to a successful development pipeline How leaders can redivert organizational resources after ending a program Why drug development failures can ultimately lead to positive outcomes